Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites

Ba, Mingchen

doi:10.3748/wjg.v16.i15.1901

Cited by 54 publications

(49 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We developed a 'BR-TRG-I type high-precision hyperthermic intraperitoneal perfusion treatment system', which allows precise automatic control of the temperature and perfusion rate of the drug solution. This system includes an automatic cooling function and adaptive fuzzy control technology for precise control of the perfusion temperature and rate, and thus, control of the local temperature in the bladder cavity of NMIBC patients (22)(23)(24)(25). To effectively kill the residual cancer cells within the bladder as well as to kill the cancer cells dropped from the bladder cavity and adhered to the bladder wall, BHPC using this device was performed immediately after the TUR of bladder tumors instead of weeks later.…”

Section: Discussionmentioning

confidence: 99%

“…According to our previous experience 3 rounds of HIPEC was used to treat abdominal tumors in order to get good outcomes (22)(23)(24)(25), consequently, BHPC was also conducted for 3 rounds in the present study. Nevertheless, for our self-developed device-based BHPC, the chemotherapeutic types of drugs and dosages involved, the treatment time and temperature are still being explored.…”

Section: Discussionmentioning

confidence: 99%

“…During hyperthermic intraperitoneal chemotherapy, widely employed in the treatment of ovarian cancer and malignant ascites with satisfactory outcomes (22)(23)(24)(25), the temperature probes sensed the temperature of the perfusion liquid or within the abdominal cavity instead of the tumor tissues directly. However, this did not hamper hyperthermia in the cancer tissues.…”

Section: Discussionmentioning

confidence: 99%

“…BHPC was performed using our novel 'BR-TRG-I type high-precision hyperthermic intraperitoneal perfusion treatment system' (Guangzhou Bright Medical Technology Co., Ltd. Guangzhou, China), in which adaptive fuzzy control technology is principally used for precise control of the drug solution perfusion temperature (±0.10̊C) and rate (±5%) (23)(24)(25)(26). The device, shown in Fig.…”

Section: Patientsmentioning

confidence: 99%

“…In addition, the pharmacokinetics of chemotherapeutic agents during thermochemotherapy is also not well understood. Over the past 6 years, we performed continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites using a novel 'BR-TRG-I type high-precision hyperthermic intraperitoneal perfusion treatment system' which can precisely maintain the temperature and perfusion rate of the drug solution, with satisfactory outcomes (22)(23)(24)(25). However, conductive BHPC for bladder cancer has been rarely reported.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection

Cui

Wang

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

Abstract. Preventing the recurrence of non-muscle invasive bladder cancer (NMIBC) post-transurethral resection (TUR) remains challenging. The aim of the present study was to investigate the effectiveness and safety of bladder intracavitary hyperthermic perfusion chemotherapy (BHPC) for prevention of NMIBC recurrence post-TUR. Between December 2006 and December 2014, 53 patients with NMIBC who underwent TUR were randomly assigned to receive BHPC (BHPC group, 28 patients) or intravesical chemotherapy alone (chemotherapy group, 25 patients) at the Intracelom Hyperthermic Perfusion Therapy Center of Guangzhou Medical University Cancer Hospital (Guangzhou, China). BHPC was performed by combining perfusion-based hyperthermia with chemotherapeutic agent mitomycin C (MMC) in the bladder, and the chemotherapy group of patients received bladder MMC perfusion. The concentration of MMC in the perfusion fluid and serum were assessed at different time-points. Tumor recurrence, disease-free survival (DFS), and side-effects were recorded and compared between the 2 groups. Results revealed that BHPC was performed smoothly, at ~44̊C in the bladder cavity. Patients tolerated BHPC, and no side-effects were observed. Both BHPC and intravesical chemotherapy achieved a high MMC concentration in the bladder perfusion liquid, but low MMC concentration in the serum, although serum MMC concentrations in the BHPC group were significantly higher (P<0.05). The tumor recurrence rate was significantly lower (10.7 vs. 28.0%; P=0.02) and the DFS period was significantly longer (37±1.2 vs. 19±0.9 months; P=0.001) in the BHPC group than in the chemotherapy group. Our results demonstrated that BHPC is safe and effective for preventing NMIBC recurrence post-TUR and prolongs DFS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection

Cui

Wang

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

show abstract

The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations

Plana¹,

Izquierdo²,

Schuitevoerder³

et al. 2020

Cancer

View full text Add to dashboard Cite

The Chicago Consensus Working Group provides multidisciplinary recommendations for palliative care specifically related to peritoneal surface malignancies. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, gynecologic oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. Cancer 2020;126:2571-2576.Octreotide is a synthetic peptide mimicking the natural effects of somatostatin, thereby reducing gastrointestinal secretions and gastrointestinal motility. In multiple studies, octreotide has been demonstrated to reduce vomiting episodes and gastrointestinal symptoms. 17,18 In addition, quality-of-life scores have improved with the use of octreotide in nonrandomized clinical studies. 19,20 When compared with anticholinergic therapies,

show abstract

Minimally Invasive Hyperthermic Intraperitoneal Perfusion for Gastric Cancer

Newhook

Badgwell

2019

Minimally Invasive Surgical Techniques for Cancers of the Gastrointestinal Tract

View full text Add to dashboard Cite

Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites

Abstract: Laparoscope-assisted CHIPC is a safe, feasible and effective procedure in the treatment of debilitating malignant ascites induced by unresectable gastric cancers.

Cited by 54 publications

References 15 publications

Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection

Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection

The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations

Minimally Invasive Hyperthermic Intraperitoneal Perfusion for Gastric Cancer

Contact Info

Product

Resources

About